FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Adenocarcinoma | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Kidney Cancer | Renal Cell Carcinoma